Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | SQLE | Q14534 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | ICMT | O60725 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8700830 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10509048 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10509053 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9492196 | 0.90 | — | — | |
| SCHEMBL2771003 | 0.90 | — | — | |
| SCHEMBL23802597 | 0.85 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL890053 | 0.85 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL21639794 | 0.85 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8013144 | 0.85 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL8819997 | 0.85 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197078-B | Pegylated lipid and modified liposome thereof, pharmaceutical composition containing liposome and preparation and application of pharmaceutical composition | 厦门赛诺邦格生物科技股份有限公司 | 2024-06-04 | — | — | CN | claimed |
| EP-4321504-A1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | claimed |
| CN-117510830-A | Pegylated lipid and modified liposome thereof, pharmaceutical composition containing liposome and preparation and application of pharmaceutical composition | 厦门赛诺邦格生物科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117327270-A | Pegylated lipid and modified liposome thereof, pharmaceutical composition containing liposome and preparation and application of pharmaceutical composition | 厦门赛诺邦格生物科技股份有限公司 | 2024-01-02 | — | — | CN | claimed |
| CN-117304473-A | Pegylated lipid and modified liposome thereof, pharmaceutical composition containing liposome and preparation and application of pharmaceutical composition | 厦门赛诺邦格生物科技股份有限公司 | 2023-12-29 | — | — | CN | claimed |
| EP-4276090-A1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2023-11-15 | — | — | EP | claimed |
| EP-2816053-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2021-03-24 | — | — | EP | claimed |
| US-20210009495-A1 | METHOD FOR THE ISOMERIZATION OF A 3-(Z)-UNSATURATED CARBOXYLIC ACID TO THE 3-(E)-ISOMER | BASF SE (DE) | 2021-01-14 | — | — | US | claimed |
| EP-3752478-A1 | METHOD FOR THE ISOMERIZATION OF A 3-(Z)-UNSATURATED CARBOXYLIC ACID TO THE 3-(E)-ISOMER | BASF SE (DE) | 2020-12-23 | — | — | EP | claimed |
| CN-111741943-A | Process for isomerizing 3- (Z) -unsaturated carboxylic acids to 3- (E) -isomers | 巴斯夫欧洲公司 | 2020-10-02 | — | — | CN | claimed |
| EP-2816053-A1 | BASE-PROTECTED OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-12-24 | — | — | EP | claimed |
| EP-2792368-A1 | LIPID NANOPARTICLES CONTAINING COMBINATIONS OF CATIONIC LIPIDS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-10-22 | — | — | EP | claimed |
| US-8846885-B2 | Oligonucleotide with protected base | AJINOMOTO CO., INC. (JP) | 2014-09-30 | — | — | US | claimed |
| EP-2774912-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-09-10 | — | — | EP | claimed |
| US-20140044755-A1 | RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF KRAS GENE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-02-13 | — | — | US | claimed |
| US-20140045913-A1 | LIPID NANO PARTICLES COMPRISING COMBINATION OF CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-02-13 | — | — | US | claimed |
| US-20130280305-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-24 | — | — | US | claimed |
| US-20130267697-A1 | OLIGONUCLEOTIDE WITH PROTECTED BASE | AJINOMOTO CO., INC. (JP) | 2013-10-10 | — | — | US | claimed |
| US-20130108685-A1 | CATIONIC LIPID | KYOWA KIRIN CO., LTD. (JP) | 2013-05-02 | — | — | US | claimed |
| EP-2567951-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045913-A1 | LIPID NANO PARTICLES COMPRISING COMBINATION OF CATIONIC LIPID | LPAR3, APOL1, PLIN3 | KMT2A 3110/4885MAPT 4116/4885MEN1 2209/4885 |
| US-20130108685-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | KMT2A 2504/4885MAPT 4637/4885MEN1 2079/4885 |
| US-20130280305-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | KMT2A 2504/4885MAPT 4637/4885MEN1 2079/4885 |
| US-20210009495-A1 | METHOD FOR THE ISOMERIZATION OF A 3-(Z)-UNSATURATED CARBOXYLIC ACID TO THE 3-(E)-ISOMER | HCAR2, HCAR1, AKR1C3 | KMT2A 2629/4885MAPT 4842/4885MEN1 3160/4885 |
| US-20130267697-A1 | OLIGONUCLEOTIDE WITH PROTECTED BASE | POLRMT, POLN, RNGTT | KMT2A 2562/4885MAPT 2765/4885MEN1 3770/4885 |
| US-20140044755-A1 | RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF KRAS GENE | KRAS, NRAS, HRAS | KMT2A 1416/4885MAPT 4620/4885MEN1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.